MMS21 Antibody

What is MMS21 and what is its primary function in cellular processes?

MMS21, also known as NSE2, is a SUMO E3 ligase enzyme that functions primarily in the post-translational modification process of sumoylation. With a molecular weight of approximately 54 kDa, it serves as a component of the SMC5-SMC6 complex involved in DNA double-strand break repair through homologous recombination . MMS21's most significant function is preventing DNA damage-induced apoptosis by facilitating DNA repair mechanisms in human cells. Additionally, MMS21-dependent sumoylation plays a crucial role in cohesion mechanisms and mitotic progression, a function that appears to operate independently of SMC6 . At the molecular level, MMS21 catalyzes the attachment of SUMO (Small Ubiquitin-like Modifier) proteins to various substrates including SMC6L1, TRAX, and potentially the cohesin components RAD21 and STAG2 .

How do researchers differentiate between MMS21 and other SUMO ligases when using antibodies?

Researchers differentiate MMS21 from other SUMO ligases through several methodological approaches. First, using highly specific antibodies raised against unique peptide sequences within MMS21, such as those within the Human NSMCE2 aa 150 to C-terminus region, allows for selective detection . When performing immunoprecipitation experiments, validation through known MMS21 substrates and molecular weight verification (~54 kDa) provides additional confirmation.

The specificity can be further validated through comparing immunoblotting patterns between wild-type cells and MMS21-depleted cells. For instance, studies have employed custom-made antibodies against MMS21, as described by Potts and Yu (2005), demonstrating that careful antibody selection is essential for distinguishing between SUMO ligases with similar structures or functions . Additionally, examining co-localization with the SMC5/6 complex components can help differentiate MMS21 from other SUMO ligases that may associate with different protein complexes.

What are the optimal sample preparation methods for detecting MMS21 using antibodies?

For optimal detection of MMS21 using antibodies, researchers should consider several critical preparation factors. When studying MMS21-dependent sumoylation processes, protein denaturing buffer conditions are essential as demonstrated in studies where cells transfected with MMS21 and His-GFP-SUMO plasmids were lysed under denaturing conditions before Ni²⁺ bead pull-down . This approach prevents SUMO proteases from removing SUMO modifications during sample preparation.

For immunoprecipitation experiments, which are suitable applications for MMS21 antibodies such as ab241347, maintaining native protein interactions may require mild lysis buffers containing appropriate protease and SUMO protease inhibitors . When studying DNA damage contexts, researchers should consider synchronized cell populations and appropriate timepoints after damage induction, as MMS21 activity may be temporally regulated in relation to DNA repair processes. Fractionation experiments have shown that DNA damage does not induce global changes in the composition of MMS21-containing complexes, suggesting that subcellular fractionation to enrich for chromatin-bound proteins may enhance detection sensitivity for the small pool of MMS21 that localizes to DNA damage sites .

What are the key substrates of MMS21's SUMO ligase activity that can be studied using antibodies?

MMS21 catalyzes the sumoylation of several important substrates that can be investigated using antibodies. The cohesin subunit Scc1 represents a well-characterized target of MMS21, with evidence demonstrating that MMS21 promotes Scc1 sumoylation at multiple sites rather than forming SUMO chains, as confirmed through experiments with SUMO1 K-less mutants (having all lysines mutated to arginine) . In addition to Scc1, MMS21 mediates SUMO attachment to SMC6L1 and TRAX, and possibly other cohesin components including RAD21 and STAG2 .

For studying these substrates, researchers should employ an experimental approach that combines overexpression of tagged SUMO proteins with Ni²⁺ bead pull-down under denaturing conditions, followed by immunoblotting with antibodies against the substrate of interest. This methodology has successfully detected sumoylated Scc1 bands that were enriched by Ni²⁺ bead pull-down, confirming their status as Scc1-SUMO conjugates . For endogenous detection, antibodies against both MMS21 and its substrates may be used in proximity ligation assays to visualize interactions at specific cellular locations such as DNA damage sites.

How can MMS21 antibody be used to investigate the role of sumoylation in DNA damage repair?

MMS21 antibodies can be instrumental in investigating sumoylation in DNA damage repair through several sophisticated approaches. Chromatin immunoprecipitation (ChIP) using MMS21 antibodies, followed by sequencing or qPCR, can reveal MMS21 recruitment to specific genomic loci after DNA damage. This technique can be paired with laser microirradiation studies, where cells are subjected to localized DNA damage followed by immunofluorescence with MMS21 antibodies to visualize recruitment kinetics.

For mechanistic studies, researchers have demonstrated that MMS21 is required for sister chromatid recombination (SCR), as evidenced by experiments where Mms21 depletion rendered HeLa cells sensitive to ionizing radiation (IR) and decreased sister chromatid exchange (SCE) frequency . To investigate this process, MMS21 antibodies can be used in conjunction with markers of DNA damage (γH2AX) and repair (RAD51, BRCA1) to establish temporal recruitment patterns at damage sites.

Additionally, MMS21 antibodies can help identify novel substrates by performing immunoprecipitation of MMS21 followed by mass spectrometry analysis of associated proteins. This approach can be enhanced by using systems with inducible DNA damage, allowing researchers to identify damage-specific interactions and sumoylation targets.

What experimental approaches can effectively demonstrate the interaction between MMS21 and the cohesin complex?

To effectively demonstrate the interaction between MMS21 and the cohesin complex, researchers should employ multiple complementary techniques. Biochemical fractionation studies have shown that most MMS21 exists as a component of the Smc5/6 complex in human cells with or without DNA damage, with cohesin subunits eluting in separate fractions . This suggests the interaction may be transient and context-dependent.

More sensitive approaches include in situ proximity ligation assays (PLA) that can detect transient or weak protein-protein interactions at specific cellular locations. For functional studies, researchers can employ recombinant protein systems, as demonstrated by experiments showing that recombinant MMS21 purified from bacteria could stimulate the sumoylation of in vitro translated Myc-Scc1 or Scc1F fragments in the presence of SUMO1, Aos1/Uba2 (E1), and Ubc9 (E2) . This approach confirms that MMS21 is sufficient to sumoylate Scc1 in vitro, even though the interactions in vivo might involve intact complexes rather than individual proteins.

How does MMS21-dependent sumoylation counteract Wapl activity in sister chromatid recombination?

MMS21-dependent sumoylation counteracts Wapl activity in sister chromatid recombination (SCR) through a functional antagonism that has been demonstrated through multiple experimental approaches. Wapl acts as a negative regulator of cohesin throughout the cell cycle, and research suggests that MMS21 promotes cohesin's function at double-strand breaks (DSBs) by opposing Wapl's activity .

The antagonistic relationship has been demonstrated through three key experimental approaches: First, colony survival assays showed that while MMS21 depletion rendered HeLa cells sensitive to ionizing radiation (IR), codepletion of Wapl along with MMS21 rescued this IR sensitivity . Second, sister chromatid exchange (SCE) assays revealed that codepletion of MMS21 and Wapl restored the SCE frequency to that of control cells . Finally, using a GFP-based gene targeting assay, researchers found that while Wapl depletion alone did not alter gene targeting efficiency, it nullified the increase in gene targeting caused by MMS21 depletion .

To investigate this mechanism using antibodies, researchers can employ immunofluorescence to track cohesin stability at DNA damage sites in cells with various combinations of MMS21 and Wapl depletion/overexpression. ChIP experiments with cohesin antibodies can measure cohesin residence time at damage sites under these different conditions, correlating findings with sumoylation status as detected by SUMO and MMS21 antibodies.

What techniques and conditions are most effective for detecting MMS21-dependent sumoylation of endogenous cohesin?

Detecting MMS21-dependent sumoylation of endogenous cohesin presents a significant challenge, as research indicates only a small pool of cohesin at DSBs is sumoylated . To overcome this limitation, several specialized techniques and conditions should be considered.

First, enrichment strategies are essential - researchers have successfully employed Ni²⁺ bead pull-down from cells expressing His-tagged SUMO proteins lysed under denaturing conditions, followed by immunoblotting with anti-Scc1 antibodies . This approach prevents SUMO proteases from removing the modification during sample preparation.

For studying endogenous sumoylation without overexpression systems, proximity ligation assays combining antibodies against cohesin subunits and SUMO proteins can detect rare sumoylation events in situ. Chromatin immunoprecipitation followed by SUMO immunoblotting may also enrich the small fraction of sumoylated cohesin at specific genomic locations.

Temporal considerations are crucial - experiments should focus on appropriate cell cycle phases (particularly G2) when cohesin is most active in DNA repair. Additionally, rapid isolation techniques are necessary due to the highly dynamic nature of sumoylation, which contributes to low steady-state levels of sumoylated proteins . The use of SUMO protease inhibitors (like N-ethylmaleimide) in all buffers and conducting experiments at reduced temperatures can help preserve these modifications.

How can researchers quantify the dynamics of antibody responses related to MMS21 activity in disease models?

Researchers can quantify antibody response dynamics related to MMS21 activity in disease models through mathematical modeling approaches that capture temporal changes. While not directly about MMS21, the search results describe methodologies that can be adapted to study MMS21-related immune responses. For example, topological data analysis has been used to highlight differences in antibody dynamics between patient groups with varying disease severity .

When studying MMS21's role in disease contexts, similar mathematical models could be developed by first collecting kinetic data on MMS21 activity, sumoylation levels, and downstream effects on DNA repair at multiple timepoints. The Akaike Information Criterion (AIC) can then be used for model selection to determine which mathematical representation best captures the dynamics of MMS21-mediated processes .

Different models can be developed to quantify dynamics between experimental groups, such as comparing wild-type versus MMS21-mutant cells in response to DNA damaging agents. These models would incorporate parameters representing cellular processes like proliferation rates, DNA repair efficiency, and cell death, allowing researchers to identify which parameters are most affected by alterations in MMS21 activity.

The resulting quantitative understanding can help identify critical time points for intervention or key parameters that distinguish pathological from normal responses, similar to how mathematical modeling helped identify that early B cell production and seroconversion process activation may lead to less effective antibody responses in severe COVID-19 patients .

What are the optimal immunoprecipitation conditions when using MMS21 antibodies?

For optimal immunoprecipitation (IP) with MMS21 antibodies, researchers should consider several methodological factors. Based on available antibody information, such as the rabbit polyclonal MMS21 antibody (ab241347) which is specifically suitable for IP applications, researchers should start with standard IP protocols using appropriate lysis buffers that preserve protein-protein interactions .

When studying MMS21 in the context of DNA damage repair, cell synchronization in G2 phase may be beneficial, as fractionation experiments have shown that DNA damage does not significantly alter the fractionation profiles of Smc5/6 components, suggesting that specific cell cycle phases might be more relevant than damage induction alone .

For detecting transient interactions between MMS21 and its substrates, crosslinking approaches may be necessary. Chemical crosslinkers that preserve protein-protein interactions can be applied before cell lysis to capture dynamic or weak interactions that might otherwise be lost during the IP procedure. Additionally, since MMS21 functions as part of the SMC5/6 complex, IP conditions should be optimized to either maintain the integrity of this complex (for co-IP studies) or to specifically isolate MMS21 (for studying MMS21-specific interactions).

When investigating MMS21-dependent sumoylation, incorporating SUMO protease inhibitors like N-ethylmaleimide in lysis buffers is crucial to prevent desumoylation during sample preparation. This is particularly important given that the steady-state levels of sumoylated proteins are typically low due to the dynamic nature of this modification .

What are the key controls needed when conducting experiments with MMS21 antibodies?

When conducting experiments with MMS21 antibodies, several key controls are essential to ensure reliable and interpretable results. First, specificity controls are critical - researchers should include samples from MMS21-depleted cells (via siRNA or CRISPR) as negative controls to confirm antibody specificity. Positive controls can include samples from cells overexpressing MMS21 or cells treated with agents known to increase MMS21 expression or activity.

For immunofluorescence or immunohistochemistry applications, peptide competition assays can help validate antibody specificity, where the antibody is pre-incubated with the immunogen peptide before application to samples, which should abolish specific staining. Additionally, when studying MMS21-dependent sumoylation, appropriate controls include samples expressing SUMO mutants (such as SUMO1 K-less or SUMO2 K11R) to differentiate between multi-site sumoylation and SUMO chain formation .

When investigating MMS21's role in DNA repair, experimental controls should include both non-damaged cells and cells treated with different DNA damaging agents to establish damage-specific responses. Time-course experiments with appropriate controls at each time point are also valuable for understanding the temporal dynamics of MMS21 recruitment and activity.

For co-localization studies, controls using antibodies against known MMS21 interactors (such as components of the SMC5/6 complex) can help confirm the relevance of observed staining patterns. Finally, when performing functional studies like those examining the antagonism between MMS21 and Wapl, appropriate controls include single depletions of each protein alongside the co-depletion condition to properly interpret the results .

How can contradictory findings regarding MMS21 function be reconciled using appropriate antibody-based techniques?

Reconciling contradictory findings regarding MMS21 function requires sophisticated antibody-based techniques and careful experimental design. First, researchers should ensure antibody specificity through validation in multiple systems, including western blotting with positive and negative controls, and verification with multiple antibodies targeting different epitopes of MMS21.

When faced with contradictory findings about MMS21's interaction with cohesin, researchers can employ proximity ligation assays (PLA) that provide higher sensitivity than traditional co-immunoprecipitation. This approach can detect transient or context-specific interactions that might be missed by other methods, potentially explaining why direct physical interactions between endogenous Scc1 and MMS21 have been difficult to detect in human cells with or without IR .

For conflicting results regarding the necessity of intact complexes for MMS21 activity, researchers can use in vitro sumoylation assays with recombinant proteins alongside cellular studies. For instance, research has shown that recombinant MMS21 can stimulate Scc1 sumoylation in vitro, while cellular studies suggest involvement of intact complexes . This apparent contradiction can be resolved by investigating whether different experimental contexts (in vitro vs. in vivo) reflect different biological realities rather than true contradictions.

When studying the small pool of sumoylated cohesin at DSBs that has proven difficult to detect biochemically, researchers can employ laser microirradiation combined with proximity ligation using antibodies against cohesin subunits and SUMO. This approach can provide spatial resolution of rare modification events that might be diluted in whole-cell biochemical assays.

What emerging technologies might enhance the study of MMS21 using antibodies?

Emerging technologies promise to significantly enhance MMS21 antibody-based research by overcoming current limitations in sensitivity and resolution. Super-resolution microscopy techniques like STORM and PALM can provide unprecedented spatial detail when using MMS21 antibodies for immunofluorescence, potentially revealing nanoscale organization of MMS21 at DNA damage sites that conventional microscopy cannot detect.

Proximity-based biotinylation methods (BioID or TurboID) combined with MMS21 antibodies could help identify transient or weak interactors that are difficult to capture with traditional immunoprecipitation. By fusing a biotin ligase to MMS21, researchers can label proximal proteins in living cells before using streptavidin pull-down and mass spectrometry to identify the labeled proteins, potentially uncovering novel substrates or regulators.

CRISPR-based genomic tagging strategies could allow endogenous tagging of MMS21 with split fluorescent proteins or epitope tags, enabling live-cell imaging of MMS21 dynamics and more efficient immunoprecipitation without overexpression artifacts. This approach, combined with advanced microscopy techniques like lattice light-sheet microscopy, could provide insights into the real-time dynamics of MMS21 at DNA damage sites.

Single-cell proteomics technologies are also emerging as powerful tools that could be applied to study cell-to-cell variation in MMS21 activity and sumoylation patterns across different cell cycle phases or in response to DNA damage, potentially explaining seemingly contradictory results obtained from bulk cell analyses.

How might MMS21 antibody research inform therapeutic approaches for DNA repair disorders?

MMS21 antibody research has significant potential to inform therapeutic approaches for DNA repair disorders by elucidating mechanisms that could be targeted pharmacologically. Since MMS21 plays a crucial role in sister chromatid recombination and counteracts Wapl to promote DNA repair , understanding these pathways could reveal druggable targets for disorders characterized by defective DNA repair.

The antagonistic relationship between MMS21 and Wapl presents a particularly promising therapeutic avenue. Research has demonstrated that depleting Wapl can rescue the DNA repair defects caused by MMS21 depletion , suggesting that inhibitors of Wapl might prove beneficial in contexts where MMS21 function is compromised. MMS21 antibodies can facilitate the identification and validation of such therapeutic targets through techniques like ChIP-seq to map genome-wide binding patterns or immunoprecipitation followed by mass spectrometry to identify interactors.

For precision medicine approaches, MMS21 antibodies could be used to develop diagnostic assays that assess MMS21 expression, localization, or activity in patient samples. Such assays might help stratify patients with DNA repair disorders according to their MMS21 status, potentially guiding treatment decisions. Additionally, high-throughput screening platforms using MMS21 antibodies could help identify compounds that enhance MMS21 activity or mimic its effects on downstream pathways when MMS21 itself is dysfunctional.

Importantly, since MMS21 functions in the sumoylation pathway, which is increasingly recognized as a crucial regulator of numerous cellular processes, insights gained from MMS21 antibody research might have broader implications beyond DNA repair disorders, potentially informing therapeutic strategies for cancer, neurodegeneration, or other conditions characterized by dysregulated sumoylation.

What are the optimal storage and handling conditions for maintaining MMS21 antibody efficacy?

For optimal storage and handling of MMS21 antibodies, researchers should follow specific protocols to maintain efficacy. Most commercially available antibodies, including those against MMS21, should be stored at -20°C for long-term preservation or at 4°C for short-term use. When handling the antibody, aliquoting into smaller volumes upon first thaw is recommended to minimize freeze-thaw cycles, which can degrade antibody quality over time.

For working solutions, antibodies should be diluted in appropriate buffers containing stabilizers like BSA (typically 1-5%) and preservatives such as sodium azide (0.02-0.05%). The optimal dilution factors for different applications (western blotting, immunoprecipitation, immunofluorescence) should be determined empirically, starting with manufacturer recommendations. For instance, the rabbit polyclonal MMS21 antibody (ab241347) has specified applications for immunoprecipitation with human samples .

When using MMS21 antibodies for detecting sumoylated proteins, special consideration should be given to preventing desumoylation during sample preparation. This includes using denaturing conditions and adding SUMO protease inhibitors like N-ethylmaleimide to all buffers, as demonstrated in protocols where cells were lysed with protein-denaturing buffer before Ni²⁺ bead pull-down .